OA18878A - Vaccine against RSV - Google Patents
Vaccine against RSV Download PDFInfo
- Publication number
- OA18878A OA18878A OA1201800362 OA18878A OA 18878 A OA18878 A OA 18878A OA 1201800362 OA1201800362 OA 1201800362 OA 18878 A OA18878 A OA 18878A
- Authority
- OA
- OAPI
- Prior art keywords
- rsv
- protein
- nucleic acid
- adenovirus
- fusion
- Prior art date
Links
- 229960005486 vaccines Drugs 0.000 title claims abstract description 46
- 241000724205 Rice stripe tenuivirus Species 0.000 title 1
- 241000725643 Respiratory syncytial virus Species 0.000 claims abstract description 271
- 108060003023 F Proteins 0.000 claims abstract description 117
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 73
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 65
- 230000004927 fusion Effects 0.000 claims abstract description 63
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 4
- 241000701161 unidentified adenovirus Species 0.000 claims description 83
- 239000000203 mixture Substances 0.000 claims description 49
- 102000004169 proteins and genes Human genes 0.000 claims description 46
- 108090000623 proteins and genes Proteins 0.000 claims description 46
- 241000282414 Homo sapiens Species 0.000 claims description 17
- 201000009910 diseases by infectious agent Diseases 0.000 claims description 15
- 241000598171 Human adenovirus sp. Species 0.000 claims description 10
- 229920001850 Nucleic acid sequence Polymers 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 108020004705 Codon Proteins 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000001902 propagating Effects 0.000 claims description 4
- 210000004027 cells Anatomy 0.000 description 131
- 108090001123 antibodies Proteins 0.000 description 40
- 102000004965 antibodies Human genes 0.000 description 40
- 230000035492 administration Effects 0.000 description 34
- 150000001413 amino acids Chemical group 0.000 description 31
- 241000700605 Viruses Species 0.000 description 26
- 230000035772 mutation Effects 0.000 description 18
- 238000010186 staining Methods 0.000 description 17
- 238000004166 bioassay Methods 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 13
- 238000006467 substitution reaction Methods 0.000 description 13
- 238000000684 flow cytometry Methods 0.000 description 12
- 230000003612 virological Effects 0.000 description 12
- 239000000427 antigen Substances 0.000 description 10
- 108091007172 antigens Proteins 0.000 description 10
- 102000038129 antigens Human genes 0.000 description 10
- 230000000240 adjuvant Effects 0.000 description 9
- 239000002671 adjuvant Substances 0.000 description 9
- 230000003053 immunization Effects 0.000 description 9
- 230000002934 lysing Effects 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 102200063764 SMG7 K66E Human genes 0.000 description 8
- 241000144282 Sigmodon Species 0.000 description 8
- 230000009089 cytolysis Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 230000028993 immune response Effects 0.000 description 8
- 230000001965 increased Effects 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 241000144290 Sigmodon hispidus Species 0.000 description 7
- 102200063290 VPS25 I76V Human genes 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 230000000087 stabilizing Effects 0.000 description 7
- 238000002255 vaccination Methods 0.000 description 7
- 210000004072 Lung Anatomy 0.000 description 6
- 101700080605 NUC1 Proteins 0.000 description 6
- 108010061543 Neutralizing Antibodies Proteins 0.000 description 6
- 239000003599 detergent Substances 0.000 description 6
- 239000012537 formulation buffer Substances 0.000 description 6
- 238000003306 harvesting Methods 0.000 description 6
- 239000006166 lysate Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 238000006386 neutralization reaction Methods 0.000 description 6
- 101700006494 nucA Proteins 0.000 description 6
- 206010001889 Alveolitis Diseases 0.000 description 5
- 102200065775 CAPN3 S215P Human genes 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 238000007918 intramuscular administration Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 210000001331 Nose Anatomy 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 230000000534 elicitor Effects 0.000 description 4
- 230000028996 humoral immune response Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 230000000644 propagated Effects 0.000 description 4
- 230000001681 protective Effects 0.000 description 4
- 210000001519 tissues Anatomy 0.000 description 4
- 229920001405 Coding region Polymers 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- 230000000890 antigenic Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000036755 cellular response Effects 0.000 description 3
- 230000005591 charge neutralization Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000003260 fluorescence intensity Methods 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037240 fusion proteins Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 229940035032 monophosphoryl lipid A Drugs 0.000 description 3
- 230000001264 neutralization Effects 0.000 description 3
- 230000003472 neutralizing Effects 0.000 description 3
- 230000001717 pathogenic Effects 0.000 description 3
- 244000052769 pathogens Species 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K Aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K Aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 2
- 206010006448 Bronchiolitis Diseases 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M Caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108091006011 G proteins Proteins 0.000 description 2
- 102000030007 GTP-Binding Proteins Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins Proteins 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000711920 Human orthopneumovirus Species 0.000 description 2
- 102400001093 PAK-2p27 Human genes 0.000 description 2
- 108091005771 Peptidases Proteins 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 206010038683 Respiratory disease Diseases 0.000 description 2
- 229920000978 Start codon Polymers 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 210000002845 Virion Anatomy 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 239000004411 aluminium Substances 0.000 description 2
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 2
- 229940001007 aluminium phosphate Drugs 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001413 cellular Effects 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000011026 diafiltration Methods 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 230000002708 enhancing Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 239000001963 growth media Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 201000009787 lower respiratory tract disease Diseases 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 230000036961 partial Effects 0.000 description 2
- 239000000546 pharmaceutic aid Substances 0.000 description 2
- 229920000023 polynucleotide Polymers 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 230000002516 postimmunization Effects 0.000 description 2
- 230000003389 potentiating Effects 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000002829 reduced Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 102220320732 rs1554306350 Human genes 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102100001249 ALB Human genes 0.000 description 1
- 101710027066 ALB Proteins 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 208000006673 Asthma Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100007826 C4BPA Human genes 0.000 description 1
- 101700051748 C4BPA Proteins 0.000 description 1
- 210000001266 CD8-Positive T-Lymphocytes Anatomy 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 229960003067 Cystine Drugs 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 210000000852 Deltoid Muscle Anatomy 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 229960001859 Domiphen bromide Drugs 0.000 description 1
- OJIYIVCMRYCWSE-UHFFFAOYSA-M Domiphen bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CCOC1=CC=CC=C1 OJIYIVCMRYCWSE-UHFFFAOYSA-M 0.000 description 1
- 102000033147 ERVK-25 Human genes 0.000 description 1
- 101700032127 ETX1 Proteins 0.000 description 1
- 101700029730 ETX2 Proteins 0.000 description 1
- 231100000655 Enterotoxin Toxicity 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108090001126 FURIN Proteins 0.000 description 1
- 102000004961 Furin Human genes 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 229960000310 ISOLEUCINE Drugs 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- 208000006897 Interstitial Lung Disease Diseases 0.000 description 1
- 229920002459 Intron Polymers 0.000 description 1
- 108020004391 Introns Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 210000004698 Lymphocytes Anatomy 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 description 1
- 229960001521 Motavizumab Drugs 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- 210000000440 Neutrophils Anatomy 0.000 description 1
- 229920000272 Oligonucleotide Polymers 0.000 description 1
- 102000035443 Peptidases Human genes 0.000 description 1
- 229940068968 Polysorbate 80 Drugs 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 229940107568 Pulmozyme Drugs 0.000 description 1
- 206010057190 Respiratory tract infection Diseases 0.000 description 1
- 210000001525 Retina Anatomy 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 101710040537 TNF Proteins 0.000 description 1
- 231100000765 Toxin Toxicity 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- NTGGOTYRTOXKMQ-UHFFFAOYSA-K aluminum;potassium;phosphate Chemical compound [Al+3].[K+].[O-]P([O-])([O-])=O NTGGOTYRTOXKMQ-UHFFFAOYSA-K 0.000 description 1
- 210000001776 amniocyte Anatomy 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000002238 attenuated Effects 0.000 description 1
- 230000001580 bacterial Effects 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 102000024070 binding proteins Human genes 0.000 description 1
- 108091007650 binding proteins Proteins 0.000 description 1
- 238000010364 biochemical engineering Methods 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 101710023118 btfP Proteins 0.000 description 1
- 235000021170 buffet Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 108091006028 chimera Proteins 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940001442 combination vaccines Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000001086 cytosolic Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000001516 effect on protein Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000003301 hydrolyzing Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000003308 immunostimulating Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 230000002458 infectious Effects 0.000 description 1
- 230000002757 inflammatory Effects 0.000 description 1
- 200000000003 influenza A Diseases 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004962 mammalian cells Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000000813 microbial Effects 0.000 description 1
- 230000003278 mimic Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 108010008564 motavizumab Proteins 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000045947 parasites Species 0.000 description 1
- 230000001402 polyadenylating Effects 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- ZDWVWKDAWBGPDN-UHFFFAOYSA-O propidium Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 ZDWVWKDAWBGPDN-UHFFFAOYSA-O 0.000 description 1
- 230000002685 pulmonary Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 108020003112 toxins Proteins 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 102000035402 transmembrane proteins Human genes 0.000 description 1
- 108091005683 transmembrane proteins Proteins 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
Abstract
The present invention relates to novel nucleic acid molecules encoding a pre-fusion RSV F protein or immunologically active part thereof, wherein the pre-fusion RSV F protein comprises the amino acid sequence of SEQ ID NO: 1 or 2. The invention further relates to the use of the nucleic acid molecules, or vectors comprising said nucleic acid molecules, as a vaccine against respiratory syncytial virus (RSV).
Description
Janssen Vaccines & Prévention B.V.
Vaccine against RSV
The invention relates to the field of medicine. More in particular, the invention relates to vaccines against RSV.
Background of the invention
Respiratory syncytial virus (RSV) is a highly contagions childhood pathogen of the respiratory tract which is believed to be responsible for -200,000 childhood deaths annually. In children younger than 2 years, RSV accounts for approximately 50% of the hospitalizations due to respiratory infections, with a peak of hospitalization occurring at 2-4 months of âge. It has been reported that almost ail children will hâve experienced infection with RSV by the âge of two, and repeated infection during life is attributed to low naturel immunity. In the elderly, the RSV disease burden is similar to those caused by non-pandemic influenza A infections. A vaccine against RSV is currently not avai labié, but is desired due to the high disease burden.
RSV is a paramyxovirus, belonging to the subfamily of pneumovirinac. Its genome encodes for varions proteins, including the membrane proteins known as RSV Glycoprotein (G) and RSV fusion (F) protein which are the major antigenic targets for neutralizîng antibodies.
Unlike the RSV G protein, the F protein is conserved between RSV strains; which makes it an attractive vaccine candidate able to elicit broadly neutralizîng antibodies. The F protein is a transmembrane protein and it is incorporated in the virion membrane from cellular membrane during virus budding. The RSV F protein facilitâtes infection by fusing the viral and host-cell membranes. In the process of fusion, the F protein refolds irreversibly from a labile pre-fusion conformation to a stable post-fusion conformation. The protein precursor, F0, requires cleavage during intracellular maturation by a furin-like protease. There are two furin sites, cleavage of which results in removal of a p27 peptide and formation of two domains: an Nterminal F2 domain and a C-terminal Fl domain (Fig. I ). The F2 and Fl domains are connected by two cystine bridges. Antibodies against the fusion protein can prevent virus uptake in the cell and thus hâve a neutralizîng effect. Besides being a target for neutralizîng antibodies, RSV F contains cytotoxic T cell epitopes (Pemberton et al, 1987, J. Gen.Virol. 68: 2177-2182).
Despite 50 years of research, there is still no licensed vaccine against RSV. One major obstacle to the vaccine development is the legacy of vaccine-enhanced disease in a clinical trial in the 1960s with a formaiin-inactivated (FI) RSV vaccine. FI-RSV vaccinated children were not protected against natural infection and infected children experienced more severe illness than non-vaccinated children, including two deaths. This phenomenon is referred to as ‘enhanced disease’.
Since the trial with the FI-RSV vaccine, various approaches to generate an RSV vaccine hâve been pursued. Attempts include classical live attenuated cold passaged or température sensitive mutant strains of RSV, (chimeric) protein subunit vaccines, peptide vaccines and RSV proteins expressed from recombinant viral vectors, including adénoviral vectors, Although some of these vaccines showed promising pre-clinical data, no vaccine has been licensed for human use due to safety concems or lack of efficacy.
Therefore, a need remains for efficient vaccines and methods of vaccinating against RSV, in particular vaccines that do not lead to enhanced disease. The present invention aims at providing such vaccines and methods for vaccinating against RSV in a safe and efficacious manner.
Summarv of the invention
The present invention provides novel nucleic acid molécules encoding stable RSV pre-fusion F proteins, wherein the RSV pre-fusion F proteins comprise the amino acid sequence of SEQ ID NO: 1 or 2.
In certain embodiments, the nucleic acid molécules encoding the RSV prefusion F proteins are codon optimized for expression in human cells.
In certain embodiments, the nucleic acid molécules encoding the RSV prefûsion F proteins comprise the nucleic acid sequence of SEQ ID NO: 3 or 4.
The invention further provides vectors comprising the nucleic acid molécules encoding RSV pre-fusion F proteins, wherein the RSV F protein comprises the amino acid sequence of SEQ ID NO: 1 or 2.
In certain embodiments, the vector is a a human recombinant adenovirus.
In certain embodiments, the recombinant adenovirus is of serotype 26 or 35.
In certain embodiments, the recombinant human adenovirus has a délétion in the El région, a délétion in the E3 région, or a délétion in both the E1 and the E3 région of the adénoviral genome.
In certain embodiments, the recombinant adenovirus has a genome comprising at its 5’ terminal ends the sequence CTATCTAT.
The invention also provides compositions, e.g. vaccines against respiratory syncytial virus (RSV), comprising a nucleic acid molécule or a vector according to the invention.
The invention further provides a method for vaccinating a subject against RSV, the method comprising administering to the subject a composition according to the invention.
In certain embodiments, the method of vaccinating a subject against RSV further comprises administering RSV F protein (preferably formulated as a pharmaceutical composition, thus a protein vaccine) to the subject.
The invention also provides a method for reducing infection and/or réplication of RSV in, e.g. the nasal tract and lungs of, a subject, comprising administering to the subject a composition comprising a nucleic acid or vector according to the invention. This will reduce adverse effects resulting from RSV infection in a subject, and thus contribute to protection of the subject against such adverse effects upon administration ofthe composition. In certain embodiments, adverse effects of RSV infection may be essentially prevented, i.e. reduced to such low levels that they are not clinically relevant.
The invention also provides an isolated host cell comprising a nucleic acid molécule encoding a RSV pre-fusion F protein, wherein the RSV pre-fusion F protein comprises the amino acid sequence of SEQ ID NO: l or 2. In certain embodiments, the nucleic acid molécule encoding the RSV pre-fusion F protein comprises the nucleic acid sequence of SEQ ID NO: 3 or 4.
The invention further provides a method for making a vaccine against respiratory syncytial virus (RSV), comprising providing a recombinant human adenovirus that comprises nucleic acid encoding a RSV pre-fusion F protein or fragment thereof, propagating said recombinant adenovirus in a culture of host cells, isolating and purifying the recombinant adenovirus, and formulating the recombinant adenovirus in a pharmaceutically acceptable composition, wherein the RSV prefusion F protein comprises the amino acid sequence of SEQ ID NO: l or 2. In certain embodiments, the recombinant adenovirus is of serotype 26 or 35.
Brief description of the Figures
FIG. I: Schematic représentation of the RSV F protein. A protein precursor includes F2 and Fl domains and p27 peptide that is removed from the mature proteins by cleavage with furin-like proteases. The cleavage sites are indicated by arrows. The numbers on top of the boxes indicate amino acid positions in the full length protein excluding signal peptide. In the Fl, structural éléments are shown: fusion peptide (FP), refolding région l (RRl) including heptad repeat A (HRA) and refolding région 2 (RR2) including heptad repeat B (HRB).
FIG. 2: Relative surface expression of F protein variants. Full length variants of F protein were expressed in HEK293T cells. The cell were stained with anti-RSV F antibody (CR95O3) and analyzed by Flow Cytometry (FACS). The Mean Fluorescent Intensity (MFI) values were calculated and normalized to MFI of control F wild type (Fwt)-transfected cell sample. The MFI of Fwt was set to 1. Bars represent mean values, error bars represent range of values.
FIG. 3: Fraction of pre-fusion F protein on cell surface. Full length variants of F protein were expressed in HEK293T cells. The cell were stained with anti-RSV F antibody CR9503 and anti-pre-fusion RSV F antibody CR9501 and analyzed by Flow Cytometry. The Mean Fluorescent Intensity (MFI) values were calculated and MFI measured by CR9501 was normalized to MFI measured by CR9503. The normalized MFI values indicate fraction of the pre-F on the cell surface. Bars represent mean values, error bars represent range of values.
FIG.4: Relative surface expression of F protein variants. Soluble versions with the transmembrane région and cytoplasmic région deleted (Fsl) and full length variants of F protein were expressed in HEK293T cells. The expression level of the soluble protein was measured in the culture supematant by octet and the full length variants were tested by cell staining using anti-RSV F antibody (CR9503) and analyzed by Flow Cytometry. The Mean Fluorescent Intensity (MFI) values were calculated and normalized to MFI of control F wild type (Fwt)-transfected cell sample. The MFI of Fwt was set to 1. Bars represent mean values, error bars represent range of values.
FIG. 5: Température stability of the F protein variants. Full length variants of F protein were expressed in HEK293T cells. After heat-shock, the cell were stained with anti-RSV F antibody (CR9501 - solid Unes and CR95O3 - dashed lines) and analyzed by Flow Cytometry. The percentage of cells positive for the staining was determined. Symbols represent mean values, error bars represent range of values. (A) The percentage of cells positive for the staining was determined. (B) The Mean Fluorescent Intensity (MFI) values were calculated and normalized to MFI of 37C cell sample. The MFI of37°C sample was set to l. Dotted lines correspond to background 5 staining at 60°C.
FIG. 6: Stability of the F proteins. PreF is more stable than FA2 protein in prefusion conformation on the cell surface in the heat-stress assay. A549 cells were infected with Ad26 and Ad35 comprising the insert FA2 (wt RSV F, grey bars) or prefusion F stabilized insert (preF2.2, black bars) at the indicated MOI. The cells were 10 température treated at the indicated température for 15 minutes before staining. Top: percentage of cells presenting prefusion F on their surface (detected by CR9501 antibody); bottom: percentage of cells presenting any form of the F protein, prefusion and post fusion (detected by CR9503 antibody). The values were normalized to 37°C samples. Ail bars represent a single measurement.
FIG.7: Ad26.RSV.preF2.1 and F2.2 elicit a cellular immune response after single administration in mice. Horizontal bars depict the géométrie mean of the response within a group. The background level is calculated as the 95% percentile of the spot forming units (SFU) observed in non-stimulated splénocytes, and is indicated with a dotted line.
FIG. 8: Ad26.RSV.preF2.1 and F2.2 induce increased virus neutralizing antibodies when compared to Ad26.RSV.FA2, after single immunization in mice. Balb/c mice (n=4 per group) were immunized with the indicated dose of 108 to 1010 viral particles (vp) Ad26.RSV.FA2 or Ad26.RSV.preF2.1 or Ad26.RSV.preF2.2, or with formulation buffer, and humoral immune responses were assayed in the sérum isolated 8 weeks after immunization. (A) Virus neutralizing antibodies were determined against RSV A Long using a micro-neutralization assay with an ELISA based read out. Titers are given as the log2 value of the IC50. (B)Pre-fiision or postfusion F antibody titers were determined by ELISA, and the ratio between pre- and post-fusion F antibodies for ail samples that showed pre- and post-fusion F titers above lower limit of quantification (LLoQ) was calculated. (C) Subclass ELISA was performed using post-fusion RSV F A2 as coating reagent, and the lgG2a/IgGl ratio (loglO) is plotted. Ratio’s observed for Thl (sérum derived from animais immunized with RSV F expression Adénoviral vectors) and Th2 (sérum derived from FI-RSV immunized animais) references samples are indicated with dashed lines. The LLoQ is indicated with a dotted lines (panels A), and horizontal bars represent the mean responses per group.
FIG. 9: Ad26.RSV.preF2.2 elicits antibody responses that neutralize a wide range of RSV isolâtes. Sera from Balb/c mice that were immunized with 1010 viral particles (vp) Ad26.RSV.FA2 (n=3) or Ad26.RSV.preF (n=4) or formulation buffer (n=2) were used in virus neutralization assays (micro-neutralization assay with an ELISA based read out) with the RSV A (upper panels) and B strains (lower panels) indicated. Titers are given as the log2 value of the IC50, and horizontal bars represent the mean response per group. LLoQ is indicated with a dashed line.
FIG. 10: Single immunization with Ad26.RSV.preF2.2 or Ad35.RSV.preF2.2 at low doses protects cotton rats against challenge with the homologous RSV A2. Cotton rats (Sigmodon hispidus) (n=7 to 9 per group) were immunized with the indicated doses (in vp/animal) of Ad26.RSV.preF2.2, Ad26.RSV.FA2 (left panels), Ad35.RSV.preF2.2 or Ad35.RSV.FA2 (right panels) by single întramuscular administration. Control immunizations were performed with formulation buffer, FIRSV, or intranasal application of a low dose of RSV A2. At seven weeks postimmunization animais were challenged intranasally with 105 pfù RSV A2. The lung (A-B) and nose viral titers (C-D) were determined by plaque assay 5 days after challenge. (E-F) Sera taken just before challenge were used to perform a virus neutralizing assay with the RSV A Long strain (micro-neutralization assay with an ELISA based read out). The dotted line represents the lower level of quantification (LLoQ). Horizontal bars represent the mean titer per group.
FIG. 11 : Ad26.RSV.preF2.2 or Ad35.RSV.preF2.2 immunization of cotton rats does not resuit in increased alveolitis scores after RSV A2 challenge. Cotton rats (Sigmodon hispidus) (n=7 to 9 per group) were immunized with the indicated doses (in vp/animal) of Ad26.RSV.preF2.2, Ad26.RSV.FA2 (upper panel), Ad35.RSV.preF2.2, or Ad35.RSV.FA2 (lower panel) by single întramuscular administration. Control immunizations were performed with formulation buffer, FIRSV, or intranasal application of a low dose of RSV A2. At seven weeks postimmunization animais were challenged intranasally with 105 pfü RSV A2. Alveolitis was scored by histopathological examination of one lung lobe 5 days after challenge on a non-linear scale from 0 to 4. The horizontal dotted line marks the maximal score of the control animais that were pre-exposed to RSV-A2 before challenge to mimic a natural exposure to RSV that does not lead to ERD.
Detailed description of the invention
RSV vaccines comprising human adenovirus comprising nucleic acid encoding RSV F protein hâve previously been described in WO2013/139911 and WO2013/139916. It was shown therein that recombinant adenoviruses of serotype 26 or 35 that comprise a nucleic acid encoding an RSV F protein are very effective vaccines against RSV in a well established cotton rat model and hâve improved efficacy as compared to data described earlier for Ad5 encoding RSV F protein. It was demonstrated that a single administration, even administered intramuscularly, of Ad26 or Ad35 encoding RSV F is sufficient to provide complété protection against challenge RSV réplication.
Because of the instability of the RSV F protein, however, the RSV F protein has the propensîty to prematurely refold into its more stable post-fusion conformation. This phenomenon is an intrinsic feature of the protein both in solution and on the surface of the virions. In human sera most RSV neutralizing antibodies are, however, directed against the RSV F in the the pre-fusion conformation. In the research that led to the présent invention, effort was therefore undertaken to identify modifications that stabilize RSV F protein in its pre-fusion conformation in the fiill length protein.
Several possible mutations stabilizing RSV F protein in the pre-fusion conformation hâve previously been described in W02014/174018 and W02014/202570. The nucleic acid molécules according to the présent invention encode RSV F proteins comprising a unique and spécifie subset of mutations. According to the invention it has been shown that this unique combination of mutations of the présent invention results in increased RSV F protein expression levels and stability of the RSV F protein in the pre-fusion conformation. In addition, it has been shown that the nucleic acid molécules according to the invention encode RSV F protein which is stabilized in the pre-fusion conformation, and which induces higher titers of neutralizing antibody as compared to wild type RSV F protein (as disclosed in WO2013/139911 and WO2013/139916).
In a first aspect, the présent invention thus provides novel nucleic acid molécules encoding a pre-fusion respiratory syncytial virus F protein (RSV pre-fusion F protein, or RSV pre-F protein), wherein the RSV pre-F protein comprises the amino acid sequence of SEQ ID NO: 1 or 2.
In certain embodiments, the nucleic acid molécules encode the RSV pre-F proteins of SEQ ID NO: 1 or SEQ ID NO: 2.
As used herein, the terms nucleic acid, nucleic acid molécule, nucleic acid or nucléotide sequence, and polynucleotide are used interchangeably and ail refer to the linear biopolymers (chains) made from nucléotides, including DNA and RNA.
It is understood by a skilled person that numerous different nucleic acid molécules can encode the same polypeptide as a resuit of the degeneracy of the genetic code. It is also understood that skilled persons may, using routine techniques, make nucléotide substitutions that do not affect the polypeptide sequence encoded by the polynucleotides described there to reflect the codon usage of any particular host organism in which the polypeptides are to be expressed. Therefore, unless otherwise specified, a nucleic acid molécule encoding an amino acid sequence includes ail nucléotide sequences that are degenerate versions of each other and that encode the same amino acid sequence. Nucléotide sequences that encode proteins and RNA may include introns. Sequences herein are provided from 5’ to 3’ direction, as custom in the art.
In certain embodiments, the nucleic acid molécule encodes a fragment of profusion RSV F comprising the amino acid sequence of SEQ ID NO: l or 2.
In certain embodiments, the nucleic acid molécules encoding the RSV prefusion F protein, or fragment thereof, are codon optimized for expression in mammalian cells, such as human cells. Methods of codon-optimization are known and hâve been described previously (e.g. WO 96/09378).
In certain embodiments, the nucleic acid molécule encoding the RSV prefusîon F protein comprises the nucleic acid sequence of SEQ ID NO: 3. In certain embodiments, the the nucleic acid encoding the RSV F protein comprises the nucleic acid sequence of SEQ ID NO: 4.
In certain embodiments, the nucleic acid encoding the RSV F protein consists of the the nucleic acid sequence of SEQ ID NO: 3 or 4.
The term fragment as used herein refers to a peptide that has an aminoterminal and/or carboxy-terminal and/or internai délétion, but where the remaining amino acid sequence is identical to the corresponding positions in the sequence ofthe full length RSV F protein, for example, the RSV F protein of SEQ ID NO. I or 2. It will be appreciated that for inducing an immune response and in general for vaccination purposes, a protein needs not to be full length nor hâve ail its wild type fonctions, and fragments of the protein are equally usefol. The person skilled in the art will also appreciate that changes can be made to a protein, e.g. by amino acid substitutions, délétions, additions, etc, e.g. using routine molecular biology procedures. Generally, conservative amino acid substitutions may be applied without loss of fonction or immunogenicity of a polypeptide. This can easily be checked according to routine procedures well known to the skilled person.
The présent invention also relates to vectors comprising a nucleic acid molécule encoding a pre-fusion RSV F protein comprising the amino acid sequence of SEQ ID NO: l or 2, or a fragment thereof.
According to the invention, the vector may be any vector that can be conveniently subjected to recombinant DNA procedures and can bring about expression of the nucleic acid molécule of the invention. The choice of the vector will typically dépend on the compatibility of the vector with the host cell into which the vector is to be introduced.
In certain embodiments, the vector is a human recombinant adenovirus, also referred to as recombinant adénoviral vectors. The préparation of recombinant adénoviral vectors is well known in the art. The term ‘recombinant’ for an adenovirus, as used herein implicates that it has been modified by the hand of man, e.g. it has altered terminal ends actively cloned therein and/or it comprises a heterologous gene,
i.e. it is not a naturally occurring wild type adenovirus.
In certain embodiments, an adénoviral vector according to the invention is déficient in at least one essential gene fonction of the El région, e.g. the El a région and/or the Elb région, of the adénoviral genome that is required for viral réplication. In certain embodiments, an adénoviral vector according to the invention is déficient in at least part of the non-essential E3 région. In certain embodiments, the vector is déficient in at least one essential gene function of the El région and at least part of the non-essential E3 région. The adénoviral vector can be multiply déficient, meaning that the adénoviral vector is déficient in one or more essential gene fonctions in each of two or more régions of the adénoviral genome. For example, the aforementioned El-déficient or El-, E3-deficient adénoviral vectors can be further déficient in at least one essential gene of the E4 région and/or at least one essential gene of the E2 région (e.g., the E2A région and/or E2B région).
Adénoviral vectors, methods for construction thereof and methods for propagating thereof, are well known in the art and are described in, for example, U.S. Pat. Nos. 5,559,099, 5,837,511, 5,846,782, 5,851,806, 5,994,106, 5,994,128, 5,965,541, 5,981,225, 6,040,174, 6,020,191, and 6,113,913, and Thomas Shenk,
Adenoviridae and their Réplication, M. S. Horwitz, Adenoviruses, Chapters 67 and 68, respectively, in Virology, B. N. Fields et al., eds., 3d ed., Raven Press, Ltd., New York ( 1996), and other references mentioned herein. Typically, construction of adénoviral vectors involves the use of standard molecular biological techniques, such as those described in, for example, Sambrook et al., Molecular Cloning, a Laboratory Manual, 2d ed., Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (1989), Watson et al., Recombinant DNA, 2d ed., Scientific American Books (1992), and Ausubel et al., Carrent Protocols in Molecular Biology, Wiley Interscience Publishers, NY ( 1995), and other references mentioned herein.
In certain embodiments, the adenovirus is a human adenovirus of the serotype 26 or 35. The vaccines according to the invention based on these serotypes appear more potent than the ones described in the prior art that were based on Ad5, since those failed to provide complété protection against RSV challenge réplication after a single intramuscular administration (Kim et al, 2010, Vaccine 28: 3801-3808; Kohlmann et al, 2009, J Virol 83: 12601-12610; Krause et al, 2011, Virology Journal 8:375). The serotype of the invention further generally has a low seroprevalence and/or low pre-existing neutralizing antibody titers in the human population. Recombinant adénoviral vectors of these serotypes with different transgenes are evaluated in clinical trials, and thus far shows to hâve an excellent safety profile. Préparation of rAd26 vectors is described, for example, in WO 2007/104792 and in Abbink et al., (2007) Viral 81(9): 4654-63. Exemplary genome sequences of Ad26 are found in GenBank Accession EF 153474 and in SEQ ID NO:1 of WO 2007/104792. Préparation of rAd35 vectors is described, for example, in US Patent No. 7,270,811, in WO 00/70071, and in Vogels et al., (2003) J Virol 77(15): 8263-71. Exemplary genome sequences of Ad35 are found in GenBank Accession AC 000019 and in Fig. 6ofWO 00/70071.
A recombinant adenovirus according to the invention may be replicationcompetent or replication-deficient. In certain embodiments, the adenovirus is réplication déficient, e.g. because it contains a délétion in the El région of the genome. As known to the skilled person, in case of délétions of essential régions from the adenovirus genome, the functions encoded by these régions hâve to be provided in trans, preferably by the producer cell, i.e. when parts or whole of El, E2 and/or E4 régions are deleted from the adenovirus, these hâve to be présent in the producer cell, for instance integrated in the genome thereof, or in the form of so-called helper adenovirus or helper plasmids. The adenovirus may also hâve a délétion in the E3 région, which is dispensable for réplication, and hence such a délétion does not hâve to be complemented.
A producer cell (sometimes also referred to in the art and herein as ‘packaging cell’ or ‘complementing cell’ or ‘host cell’) that can be used can be any producer cell wherein a desired adenovirus can be propagated. For example, the propagation of recombinant adenovirus vectors is done in producer cells that complément deficiencies in the adenovirus. Such producer cells preferably hâve in their genome at least an adenovirus El sequence, and thereby are capable of complementing recombinant adenoviruses with a délétion in the El région. Any El-complementing producer cell can be used, such as human retina cells immortalized by El, e.g. 911 or PER.C6 cells (see US patent 5,994,128), El-transformed amniocytes (See EP patent 1230354), El-transformed A549 cells (see e.g. WO 98/39411, US patent 5,891,690), GH329:HeLa (Gao et al, 2000, Human Gene Therapy 11: 213-219), 293, and the like. In certain embodiments, the producer cells are for instance HEK293 cells, or PER.C6 cells, or 911 cells, or IT293SF cells, and the like.
For non-subgroup C El-déficient adenoviruses such as Ad35 (subgroup B) or Ad26 (subgroup D), it is preferred to exchange the E4-orf6 coding sequence of these non-subgroup C adenoviruses with the E4-orf6 of an adenovirus of subgroup C such as Ad5. This allows propagation of such adenoviruses in well known complementing cell fines that express the El genes of Ad5, such as for example 293 cells or PER.C6 cells (see, e.g. Havenga et al, 2006, J. Gen. Viral. 87: 2135-2143; WO 03/104467, incorporated in its entirety by reference herein). In certain embodiments, an adenovirus that can be used is a human adenovirus of serotype 35, with a délétion in the El région into which the nucleic acid encoding RSV F protein antigen has been cloned, and with an E4 orfô région of Ad5. In certain embodiments, the adenovirus in the vaccine composition of the invention is a human adenovirus of serotype 26, with a délétion in the El région into which the nucleic acid encoding RSV F protein antigen has been cloned, and with an E4 orfô région of Ad5.
In alternative embodiments, there is no need to place a heterologous E4orf6 région (e.g. of Ad5) in the adénoviral vector, but instead the El-déficient nonsubgroup C vector is propagated in a cell line that expresses both El and a compatible E4orf6, e.g. the 293-ORF6 cell line that expresses both El and E4orf6 from Ad5 (see e.g. Brough et al, 1996, J Viral 70: 6497-501 describing the génération of the 29318878
OR.F6 cells; Abrahamsen et al, 1997, J Viral 71: 8946-51 and Nan et al, 2003, Gene Therapy 10: 326-36 each describing génération of El deleted non-subgroup C adénoviral vectors using such a cell line).
Altematively, a complementing cell that expresses El from the serotype that is to be propagated can be used (see e.g. WO 00/70071, WO 02/40665).
For subgroup B adenoviruses, such as Ad35, having a délétion in the El région, it is preferred to retain the 3’ end of the El B 55K open reading frame in the adenovirus, for instance the 166 bp directly upstream of the pIX open reading frame or a fragment comprising this such as a 243 bp fragment directly upstream of the pIX start codon (marked at the 5’ end by a 5îw36I restriction site in the Ad35 genome), since this increases the stability of the adenovirus because the promoter of the pIX gene is partly residing in this area (see, e.g. Havenga et al, 2006, J. Gen. Virol. 87: 2135-2143; WO 2004/001032, incorporated by référencé herein).
“Heterologous nucleic acid” (also referred to herein as ‘transgene’) in adenoviruses of the invention is nucleic acid that is not naturally présent in the adenovirus. It is introduced into the adenovirus for instance by standard molecular biology techniques. In the présent invention, the heterologous nucleic acid encodes the RSV pre-F protein (or fragment thereof) comprising the amino acid sequence of SEQ ID NO: 1 or 2. It can for instance be cloned into a deleted El or E3 région of an adénoviral vector. A transgene is generally operably linked to expression control sequences. This can for instance be donc by piacing the nucleic acid encoding the transgene(s) under the control of a promoter. Further regulatory sequences may be added. Many promoters can be used for expression of a transgene(s), and are known to the skilled person. A non-limiting example of a suitable promoter for obtaining expression in eukaryotic cells is a CMV-promoter (US 5,385,839), e.g. the CMV immédiate early promoter, for instance comprising nt. -735 to +95 from the CMV immédiate early gene enhancer/promoter. A polyadenylation signal, for example the bovine growth hormone polyA signal (US 5,122,458), may be présent behind the transgene(s).
In certain embodiments, the recombinant adenovectors of the invention comprise as the 5’ terminal nucléotides the nucléotide sequence: CTATCTAT. These embodiments are advantageous because such vectors display improved réplication in production processes, resulting in batches of adenovirus with improved homogeneity, as compared to vectors having the original 5’ terminal sequences (generally
CATCATCA) (see also patent application nos. PCT/EP2013/054846 and US 13/794,318, entitled ‘Batches of recombinant adenovirus with altered terminal ends’ filed on 12 March 2012 in the naine ofCrucel! Holland B.V.), incorporated in its entirety by reference herein. The invention thus also provides batches of recombinant adenovirus encoding RSV F protein or a part thereof, wherein the RSV F protein comprises the amino acid sequence of SEQ ID NO: 1 or 2, and wherein essentially ail (e.g. at least 90%) of the adenoviruses in the batch comprise a genome with terminal nucléotide sequence CTATCTAT.
In certain embodiments, the nucleic acid molécule may encode a fragment of the pre-fusion F protein of RSV. The fragment may resuit from either or both of amino-terminal and carboxy-terminal délétions. The extent of délétion may be determined by a person skilled in the art to, for example, achieve better yield of the recombinant adenovirus. The fragment will be chosen to comprise an immunologically active fragment of the F protein, i.e. a part that will give rise to an immune response in a subject. This can be easily determined using in silico, in vitro and/or in vivo methods, ail routine to the skilled person.
The invention furthermore provides compositions comprising a nucleic acid molécule encoding a pre-fùsion RSV F comprising the amino acid sequence of SEQ ID NO: 1 or 2.
Also, the invention provides compositions comprising a vector as described herein.
In certain embodiments, the compositions comprising a nucleic acid molécule and/or a vector are for use in reducing infection and/or réplication of RSV in a subject. In certain preferred embodiments, the compositions are for use as a vaccine against RSV. The term vaccine refers to an agent or composition containing an active component effective to induce a therapeutic degree of immunity in a subject against a certain pathogen or disease. In the present invention, the vaccine comprises an effective amount of a nucleic acid molécule that encodes an RSV pre-fusion F protein comprising SEQ ID NO: 1 or 2, or an antigenic fragment thereof, which results in an immune response against the F protein of RSV. This provides a method of preventing serious lower respiratory tract disease leading to hospitalization and the decrease the frequency of complications such as pneumonia and bronchiolitis due to RSV infection and réplication in a subject. Thus, the invention also provides a method for preventing or reducing serious lower respiratory tract disease, preventing or reducing (e.g. shortening) hospitalization, and/or reducing the frequency and/or severity of pneumonia or bronchiolitis caused by RSV in a subject, comprising administering to the subject a composition comprising a nucleic acid molécule encoding a RSV pre-F protein or fragment thereof, wherein the RSV F protein comprises the amino acid sequence of SEQ ID NO: l or 2. The term “vaccine” according to the invention implies that it is a pharmaceutical composition, and thus typically includes a pharmaceutically acceptable diluent, carrier or excipient. It may or may not comprise further active ingrédients. In certain embodiments it may be a combination vaccine that further comprises other components that induce an immune response, e.g. against other proteins of RSV and/or against other infectious agents.
In certain embodiments the compositions comprising the nucleic acid molécule or vector further comprise, or are administered together with, one or more adjuvants. Adjuvants are known in the art to further increase the immune response to an applied antigenic déterminant, and pharmaceutical compositions comprising adenovirus and suitable adjuvants are for instance disclosed in WO 2007/110409, incorporated by reference herein. The ternis “adjuvant” and immune stimulant are used interchangeably herein, and are defined as one or more substances that cause stimulation of the immune System. In this context, an adjuvant is used to enhance an immune response to the RSV prefusion F proteins of the invention. Examples of suitable adjuvants include aluminium salts such as aluminium hydroxide and/or aluminium phosphate; oil-emulsion compositions (or oil-in-water compositions), including squalene-water émulsions, such as MF59 (see e.g. WO 90/14837); saponin formulations, such as for example QS2l and Immunostimulating Complexes (ISCOMS) (see e.g. US 5,057,540; WO 90/03184, WO 96/l I7l l, WO 2004/004762, WO 2005/002620); bacterial or microbial dérivatives, examples of which are monophosphoryl lipid A (MPL), 3-O-deacylated MPL (3dMPL), CpG-motif containing oligonucleotides, ADP-ribosylating bacterial toxins or mutants thereof, such as E. coli heat labile enterotoxin LT, choiera toxin CT, and the like. It is also possible to use vector-encoded adjuvant, e.g. by using heterologous nucleic acid that encodes a fusion of the oligomérization domain of C4-binding protein (C4bp) to the antigen of interest (e.g. Solabomi et al, 2008, Infect Immun 76: 3817-23). In certain embodiments the compositions of the invention comprise aluminium as an adjuvant, e.g. in the form of aluminium hydroxide, aluminium phosphate, aluminium potassium phosphate, or combinations thereof, in concentrations of 0.05 - 5 mg, e.g. from 0.075-
1.0 mg, of aluminium content per dose.
In other embodiments, the compositions do not comprise adjuvants.
It is also possible according to the invention to administer further active components, in combination with the compositions, e.g. vaccines, according to the invention. Such further active components may comprise e.g. other RSV antigens or vectors comprising nucleic acid encoding these. Such vectors again may be nonadenoviral or adénoviral, of which the latter can be of any serotype. An example of other RSV antigens includes RSV F or G protein or immunologically active parts thereof. For instance, intranasally applied recombinant replication-deficient Ad5 based adenovector rAd/3xG, expressing the soluble core domain of G glycoprotein (amino acids 130 to 230) was protective in a murine model (Yu et al, 2008, J Virol 82: 2350-2357), and although it was not protective when applied intramuscularly, it is clear from these data that RSV G is a suitable antigen for înducing protective responses. Further active components may also comprise non-RSV antigens, e.g. from other pathogens such as viruses, bacteria, parasites, and the like. The administration of further active components may for instance be done by separate administration or by administering combination products of the vaccines of the invention and the further active components. In certain embodiments, further non-adenoviral antigens (besides RSV.F), may be encoded in the vectors of the invention. In certain embodiments, it may thus be desired to express more than one protein from a single adenovirus, and in such cases more coding sequences for instance may be linked to form a single transcript from a single expression cassette or may be présent in two separate expression cassettes cloned in different parts of the adénoviral genome.
The compositions of the invention, e.g. the adenovirus compositions, may be administered to a subject, e.g. a human subject. The total dose of the adenovirus provided to a subject during one administration can be varied as is known to the skilled practitioner, and is generally between 1x107 viral particles (vp) and 1x1012 vp, preferably between 1x108 vp and 1x1011 vp, for instance between 3x108 and 5x 1010 vp, for instance between 109 and 3x 1010 vp.
Administration of the compositions can be performed using standard routes of administration. Non-limiting embodiments include parentéral administration, such as by injection e.g. intradermal, intramuscular, etc, or subcutaneous, transcutaneous, or mucosal administration, e.g. intranasal, oral, and the like. Intranasal administration has generally been seen as a preferred route for vaccines against RSV. The most important advantage of the live intrasal strategy is the direct stimulation of local respiratory tract immunity and the lack of associated disease enhancement. The only vaccines under clinical évaluation for pédiatrie use at the présent time are live intranasal vaccine (Collins and Murphy. Vaccines against human respiratory syncytial virus). In: Perspectives in Medical Virology 14; Respiratory Syncytial Virus (Ed. Cane, P.), Elsevier, Amsterdam, the Netherlands, pp233-277). Intranasal administration is a suitable preferred route according to the présent invention as welL The advantage of intramuscular administration is that it is simple and wellestablished, and does not carry the safety concems for intranasal application in infants younger than 6 months. In one embodiment a composition is administered by intramuscular injection, e.g. into the deltoid muscle of the arm, or vastus lateralîs muscle of the thigh. The skilled person knows the various possibilities to administer a composition, e.g. a vaccine in order to induce an immune response to the antigen(s) in the vaccine.
A subject as used herein preferably is a mammal, for instance a rodent, e.g. a mouse, a cotton rat, or a non-human-primate, or a human. Preferably, the subject is a human subject. The subject can be of any âge, e.g. from about l month to 100 years old, e.g. from about 2 months to about 80 years old, e.g. from about l month to about 3 years old, from about 3 years to about 50 years old, from about 50 years to about 75 years old, etc.
It is also possible to provide one or more booster administrations of one or compositions, e.g. the vaccines, of the invention. If a boosting vaccination is performed, typically, such a boosting vaccination will be administered to the same subject at a moment between one week and one year, preferably between two weeks and four months, after administering the composition to the subject for the first time (which is in such cases referred to as ‘priming vaccination’). In alternative boosting regimens, it is also possible to administer different vectors, e.g. one or more adenoviruses of different serotype, or other vectors such as MVA, or DNA, or protein, to the subject after the priming vaccination. It is for instance possible to administer to the subject a recombinant adénoviral vector comprising a nucleic acid sequence encoding the pre-fusion RSV F protein as a prime, and to boost with a composition comprising a RSV F protein. In certain embodiments, the RSV F protein also is stabilized in the pre-fusion conformation.
In certain embodiments, the administration comprises a primîng and at least one booster administration. In certain embodiments, the composition is administered as a priming composition and/or as a boosting composition in a prime-boost vaccination regimen. In certain embodiments thereof, the priming administration is with a rAd35 comprising nucleic acid encoding RSV pre-F protein or a fragment thereof (‘rAd35-RSV.pre-F’), wherein the RSV F pre-F protein comprises the amino acid sequence of SEQ ID NO: l or 2, and the booster administration is with a rAd26 comprising nucleic acid encoding RSV F protein (‘rAd26-RSV.pre-F’), wherein the RSV pre-F protein comprises the amino acid sequence of SEQ ID NO: l or 2. In other embodiments thereof, the priming administration is with rAd26-RSV.pre-F and the booster administration is with rAd35-RSV.pre-F. In other embodiments, both the priming and booster administration are with rAd26.RSV.pre-F. In certain embodiments, the priming administration is with rAd26-RSV.pre-F or rAd35RSV.pre-F and the booster administration is with RSV F protein. In ali these embodiments, it is possible to provide further booster administrations with the same or other vectors or protein. Embodiments where boosting with RSV F protein may be particularly bénéficiai include e.g. in elder subjects in risk groups (e.g. having COPD or asthma) of 50 years or older, or e.g. in healthy subjects of 60 years or older or 65 years or older.
In certain embodiments, the administration comprises a single administration of a composition according to the invention, without further (booster) administrations. Such embodiments are advantageous in view of the reduced complexity and costs of a single administration regimen as compared to a prime-boost regimen. Complété protection is already observed after single administration of the recombinant adénoviral vectors of the invention without booster administrations in the cotton rat model in the examples herein.
In a further aspect, the invention provides methods for making a vaccine against respiratory syncytial virus (RSV), comprising providing a recombinant human adenovirus that comprises nucleic acid encoding a RSV F protein or fragment thereof, propagating said recombinant adenovirus in a culture of host cells, isolating and purifying the recombinant adenovirus, and bringing the recombinant adenovirus in a pharmaceutically acceptable composition, wherein the RSV F protein comprises the amino acid sequence of SEQ ID NO: l or 2.
Recombinant adenovirus can be prepared and propagated in host cells, according to well known methods, which entail cell culture of the host cells that are infected with the adenovirus. The cell culture can be any type of cell culture, including adhèrent cell culture, e.g. cells attached to the surface of a culture vessel or to microcarriers, as well as suspension culture.
Most large-scale suspension cultures are operated as batch or fed-batch processes because they are the most straightforward to operate and scale up. Nowadays, continuons processes based on perfusion principles are becoming more common and are also suitable (see e.g. WO 2010/060719, and WO 2011/098592, both incorporated by reference herein, which describe suitable methods for obtaining and purifying large amounts of recombinant adenoviruses).
Producer cells are cultured to increase cell and virus numbers and/or virus titers. Culturing a cell is done to enable it to metabolize, and/or grow and/or divide and/or produce virus of interest according to the invention. This can be accomplished by methods as such well known to persons skilled in the art, and includes but is not limited to providing nutrients for the cell, for instance in the appropriate culture media. Suitable culture media are well known to the skilled person and can generally be obtained from commercial sources in large quantifies, or custom-made according to standard protocols. Culturing can be done for instance in dishes, roller bottles or in bioreactors, using batch, fed-batch, continuous Systems and the like. Suitable conditions for culturing cells are known (see e.g. Tissue Culture, Academie Press, K ruse and Paterson, editors (1973), and R.I. Freshney, Culture of animal cells: A manual of basic technique, fourth édition (Wiley-Liss Inc., 2000, ISBN 0-471-348899)·
Typically, the adenovirus will be exposed to the appropriate producer cell in a culture, permitting uptake of the virus. Usually, the optimal agitation is between about 50 and 300 rpm, typically about 100-200, e.g. about 150, typical DO is 20-60%, e.g.40%, the optimal pH is between 6.7 and 7.7, the optimal température between 30 and 39°C, e.g. 34-37°C, and the optimal MOI between 5 and 1000, e.g. about 50-300. Typically, adenovirus infects producer cells spontaneously, and bringing the producer cells into contact with rAd particles is sufficient for infection of the cells. Generally, an adenovirus seed stock is added to the culture to initiate infection, and subsequently the adenovirus propagates in the producer cells. This is ail routine for the person skilled in the art.
After infection of an adenovirus, the virus replicates înside the cell and is thereby amplified, a process referred to herein as propagation of adenovirus. Adenovirus infection results finally in the lysis of the cells being infected. The lytîc characteristics of adenovirus therefore pennits two different modes of virus production. The first mode is harvesting virus prior to cell lysis, employing extemal factors to lyse the cells. The second mode is harvesting virus supematant after (almost) complété cell lysis by the produced virus (see e.g. US patent 6,485,958, describing the harvesting of adenovirus without lysis of the host cells by an extemal factor). It is preferred to employ extemal factors to actively lyse the cells for harvesting the adenovirus.
Methods that can be used for active cell lysis are known to the person skilled in the art, and hâve for instance been discussed in WO 98/22588, p. 28-35. Useftil methods in this respect are for example, freeze-thaw, solid shear, hypertonie and/or hypotonie lysis, liquid shear, sonication, high pressure extrusion, detergent lysis, 15 combinations of the above, and the like. In one embodiment of the invention, the cells are lysed using at least one detergent. Use of a detergent for lysis has the advantage that it is an easy method, and that it is easily scalable.
Détergents that can be used, and the way they are employed, are generally known to the person skilled in the art. Several examples are for instance discussed in 20 WO 98/22588, p. 29-33. Détergents can include anionic, cationic, zwitterionic, and nonionic détergents. The concentration of the detergent may be varied, for instance within the range of about 0. l%-5% (w/w). In one embodiment, the detergent used is Triton X-100.
Nuclease may be employed to remove contaminating, i.e. mostly from the 25 producer cell, nucleic acids. Exemplary nucleases suitable for use in the présent invention include Benzonase®, Pulmozyme®, or any other DNase and/or RNase commonly used within the art. In preferred embodiments, the nuclease is Benzonase®, which rapidly hydrolyzes nucleic acids by hydrolyzing internai phosphodiester bonds between spécifie nucléotides, thereby reducing the viscosity of the cell lysate.
Benzonase can be commercially obtained from Merck KGaA (code W214950). The concentration in which the nuclease is employed is preferably within the range of I100 units/ml. Altematively, or in addition to nuclease treatment, it is also possible to selectively precipitate host cell DNA away from adenovirus préparations during adenovirus purification, using sélective precipitating agents such as domiphen bromide (see e.g. US 7,326,555; Goerke et al., 2005, Biotechnology and bioengineering, Vol. 91: 12-21; WO 2011/045378; WO 2011/04538I).
Methods for harvesting adenovirus from cultures of producer cells hâve been extensively described in WO 2005/080556.
In certain embodiments, the harvested adenovirus is further purified. Purification of the adenovirus can be performed in several steps comprising clarification, ultrafiltration, diafiltration or séparation with chromatography as described in for instance WO 05/080556, incorporated by reference herein. Clarification may be done by a filtration step, removing cell débris and other impurities from the cell lysate. Ultrafiltration is used to concentrate the virus solution. Diafiltration, or buffer exchange, using ultrafilters is a way for removal and exchange of salts, sugars and the like. The person skilled in the art knows how to find the optimal conditions for each purification step. Also WO 98/22588, incorporated in its entirety by reference herein, describes methods for the production and purification of adénoviral vectors. The methods comprise growing host cells, infecting the host cells with adenovirus, harvesting and lysing the host cells, concentrating the crude lysate, exchanging the buffer of the crude lysate, treating the lysate with nuclease, and further purifying the virus using chromatography.
Preferably, purification employs at least one chromatography step, as for instance discussed in WO 98/22588, p. 61-70. Many processes hâve been described for the further purification of adenoviruses, wherein chromatography steps are included in the process. The person skilled in the art will be aware of these processes, and can vary the exact way of employing chromatographie steps to optimize the process. It is for instance possible to purify adenoviruses by anion exchange chromatography steps, see for instance WO 2005/080556 and Konz et al, 2005, Hum Gene Ther 16: 1346-1353. Many other adenovirus purification methods hâve been described and are within the reach of the skilled person. Further methods for producing and purifying adenoviruses are disclosed in for example (WO 00/32754; WO 04/020971; US 5,837,520; US 6,261,823; WO 2006/108707; Konz et al, 2008, Methods Mol Biol 434: 13-23; Altaras et al, 2005, Adv Biochem Eng Biotechnol 99: 193-260), ail incorporated by reference herein.
For administering to humans, the invention may employ pharmaceutical compositions comprising the rAd and a pharmaceutically acceptable carrier or excipient. In the présent context, the term Pharmaceutically acceptable means that the carrier or excipient, at the dosages and concentrations employed, will not cause any unwanted or harmful effects in the subjects to which they are administered. Such pharmaceuticaily acceptable carriers and excipients are well known in the art (see Remington’s Pharmaceutical Sciences, 18th édition, A. R. Gennaro, Ed., Mack Publishing Company [l 990]; Pharmaceutical Formulation Development of Peptides and Proteins, S. Frokjaer and L. Hovgaard, Eds., Taylor & Francis [2000]; and Handbook of Pharmaceutical Excipients, 3rd édition, A. Kibbe, Ed., Pharmaceutical Press [2000]). The purified rAd preferably is formulated and administered as a stérile solution although it is also possible to utilize lyophilized préparations. Stérile solutions are prepared by stérile filtration or by other methods known per se in the art. The solutions are then lyophilized or filled into pharmaceutical dosage containers. The pH of the solution generally is in the range of pH 3.0 to 9.5, e.g pH 5.0 to 7.5. The rAd typically is in a solution having a suitable pharmaceuticaily acceptable buffer, and the solution of rAd may also contain a sait. Optionally stabilizing agent may be présent, such as albumin. In certain embodiments, detergent is added. In certain embodiments, rAd may be formulated into an injectable préparation. These formulations contain effective amounts of rAd, are either stérile liquid solutions, liquid suspensions or lyophilized versions and optionally contain stabilizers or excipients. An adenovirus vaccine can also be aerosolized for intranasal administration (see e.g. WO 2009/117134),
For instance, adenovirus may be stored in the buffer that is also used for the Adenovirus World Standard (Hoganson et al, Development of a stable adénoviral vector formulation, Bioprocessing March 2002, p. 43-48): 20 mM Tris pH 8, 25 mM NaCI, 2.5% glycerol. Another useful formulation buffer suitable for administration to humans is 20 mM Tris, 2 mM MgCh, 25 mM NaCI, sucrose 10% w/v, polysorbate-80 0.02% w/v. Obviously, many other buffers can be used, and several examples of suitable formulations for the storage and for pharmaceutical administration of purified (adeno)virus préparations can for instance be found in European patent no. 0853660, US patent 6,225,289 and in international patent applications WO 99/41416, WO 99/12568, WO 00/29024, WO 01/66137, WO 03/049763, WO 03/078592, WO 03/06l708.
The invention is further explained in the following examples. The examples do not limit the invention in any way. They merely serve to clarify the invention.
EXAMPLES
Example 1. Stabilizing the RSV F protein in its pre-fusion conformation
Plasmids encoding basic RSV F sequences were synthesized and the amino acid substitutions were introduced in the protein by site-directed mutagenesîs. The protein variants were transientiy expressed in HEK293 cells. The relative protein expression on the cell surface was assessed by Flow Cytometry. The stability ofthe F proteins in pre-fusion conformation was evaluated in a heat-stability assay.
The protein sequence used for RSV A2 F protein variants was retrieved from the GenBank, accession number ACO83301.1. The amino acid substitutions were introduced in the sequence by site-directed mutagenesîs (QuikChange II XL SiteDirected Mutagenesîs K.it, Agilent technologies). The mutagenesîs primers were designed using on-line tool PrimerX. HEK293T cells (CRL-11268) were purchased from American Tissue Culture Collection and cultured under standard cell culture conditions (37°C, 10% CO2).
Fully human IgGl anti-RSV F protein antibodies CR9501 and CR9503 were constructed by cloning the heavy (VH) and light (VL) chain variable régions into a single IgGl expression vector. PER.C6® cells (Crucell) were transfected with the IgG 1 expression constructs and the expressed antibodies were purified from culture supernatants using POROS Mabcapture A chromatography (Applied Biosystems) and then buffer exchanged to 50mM NaAc, 50mM NaCl, pH 5.5. Antibody concentration was measured by optical absorption at 280 nm. Antibody quality was also confirmed by size-exclusion chromatography (SEC), SDS-PAGE and isoelectric focusing. The antibody CR9501 comprises VH and VL régions of 58C5 (as described in WO2011/020079) which binds specifically to RSV F protein in its pre-fusion conformation and not to the post-fusion conformation. CR9503 comprises VH and VL régions of motavizumab, which recognizes both the pre-fusion and post-fusion conformation of RSV F.
Protein expression and température treatment:
The plasmids were transientiy transfected into adhèrent HEK293T cells using 293fectine (Cat# 12347-019) transfection reagents (Life Technologies) according to suppliers recommendations. 48 hours post transfection the cells were harvested by detaching with EDTA-containing FACS buffet (no trypsin, see next section) and cell suspension was heat-treated for 10 minutes either in a water bath or in PCR block for the température stability experiments. After the heat-treatment, the cells were prepared for the Flow Cytometry analysis.
For analysis of adeno expressed F proteins, A549 cells were infected with Ad26 virus at a MOI of 10 000 or 5000 and Ad35 viruses at a MOI of 5000, 2500 or l .250. After 48h, the cells were detached and heat treated for 15 minutes at 37°C, 50°C and 56°C. Upon heat treatment cells were stained using CR950l-Alexa647 or CR9503-Alexa647 and Propidium lodide (PI). After staining, the cells were fixed and analyzed using the BD FACS CANTO II cell analyzer.
Flow Cytometry analysis:
For each staining, the following Controls were included: I) négative control sample. i.e. cells that were not subjected to any treatment and not stained with any antibody labeled with a fluorophore; 2) positive control samples, i.e. cells that are stained with only one fluorophore (one of each that are used for the experiment),
The cells were resuspended in the Flow Cytometry (FC Buffer, 5mM EDTA, l% FBS in PBS) and distributed in volumes of 50 μΐ of the cell suspension per well in a 96-welI plate with a lid (U- or V-bottom plates). Two-step or one-step protocols were used for staining.
In case of the two-step protocol 50 μΐ of the first Abs (or buffer for négative Controls) was added to the wells and incubated at RT for 30min. Biotinylated CR950land CR9503 were used at 2 pg/ml (final concentration in a well l pg/ml). After incubation, the cells were washed 2 times with the FC buffer. Afterwards 50 μΐ of Streptavidin-APC (Molecular Probes cat#SAl005, 0.1 mg/ml is used at l : 100) or buffer for négative Controls was added to the wells and incubated at RT for 30min. The cells were washed again 2 times with the FC buffer. After the last wash, the cells were resuspended in 100 μΐ of FC buffer +/- live-dead stain (PI from Invitrogen, cat#Pl304MP, used at 2 pg/ml) and incubated at RT for 15 minutes. The cells were centrifuged at 200g (lOOOrpm) for 5 min., the buffer with PI was removed and the cells were resuspended in 150 μΐ of the FC buffer.
In case of a one- step protocol, CR950I and CR9503 antibodies were labeled with fluorescent probe Alexa647 (Molecular Probes, cat#A-20l86) according to manufacturées instructions. Cells were stained according to the protocol above excluding the Streptavidin-APC step.
From the live cell population, the percentage of cells positive for CR9501/CR9503 antibody binding was determined. The cells positive for CR9503 binding express RSV F protein on their surface. The cells positive for CR9501 binding express pre-fusion RSV F on their surface.
The intensity of the antibody staining (Médian fluorescence intensity - MFI) is proportional to the amount of F protein on the cell surface. MFI was calculated from the live cell population expressing F protein.
Results:
Surface cell expression of the full length F protein variants:
A subset of mutations that was previously identified to increase expression or stability of the RSV F protein ectodomain in pre-fusion conformation was introduced in the wild type full length RSV A2 F sequence (accession number Genbank ACO83301). The mutations were introduced alone or in multiple combinations, and the effect on protein expression and stability was assessed.
The expression level of the protein was measured as mean fluorescence intensity (MFI) by Flow Cytometry after staining with the CR9503 antibody that is recognizing both pre-fusion and post-fusion F protein. The combination of the two amino acid substitutions that were previously described for stabilization of the soluble RSV pre-F protein (i.e. N67I and S215P) also increased the expression level of the full length RSV F protein by 2.3-fold, relative to wilde type full length RSV F (Fig.
2).
A prominent increase in expression was observed for variants with 3 amino acid substitutions combined. Interestingly, combination of more than three mutations in one variant did not further increase protein expression. This may be due to limited capacity of the cellular membrane to accommodate multiple copies of F protein.
The amount of the pre-fusion F on the surface of the cell was assessed by staining with pre-fusion spécifie antibody CR9501 (Fig. 3). Transfection of the cells with ail F variants resulted in a more or less similar amount of pre-fusion F protein on the cell surface. Presence of the transmembrane domain stabilîzes the full length protein to certain extent and therefore différences in the pre-fusion stability are not as apparent under ambient conditions between the full length F proteins. Therefore the heat-stability assay was developed to better discriminate stability of full length variants, as decribed below.
The A2 strain that was used as a parental sequence for the previously described F protein variants (W02014/174018 and WO2014/202570) is a cell line adapted laboratory strain which has accumulated two unique and rare mutations (i.e. of Lysine 66 and Isoleucine 76). In the present invention, these two residues were mutated to match the natural clinical isolâtes (K66E, I76V). The K66E and I76V mutations were included in selected protein designs. In comparison to variants with Lys66 and Ue76, variants with glutamate at 66 (K66E) hâve a tendency to express slightly higher. Addition of valine at residue 76 (a double substitution of K66E and I76V) does not influence expression level when compared to variants with K66E substitution alone (Fig. 4).
Stability of the full length F protein variants on the cell surface:
In ambient conditions on a short time scale, no significant différence in stability of pre-fusion conformation was observed between full length F variants with the different combinations of stabilizing mutations. An elevated température is known to serve as an efficient in vitro trigger for refolding of RSV F protein from pre-fusion to post-fusion conformation. Therefore, a heat-shock assay was established and used to assess stability of the membrane-bound full length proteins. Shortly, the HEK293T cells were transfected with the F protein constructs and used for the assay 48 hours after transfection. The cells were detached from cell culture dishes and the cell suspension was heat-treated at increasing températures for 10 minutes. After the heattreatment, cells were stained with the anti-RSV F antibodies and analyzed by Flow Cytometry. The Flow Cytometry data was analyzed in two different ways. The percentage of the cells, positive for staining with the anti-F antibodies was analyzed, and also mean fluorescence intensity (MFI) of the positive cells was calculated (Fig. 5).
Both staining with CR.9501 (antibody recognizing only pre-fusion F protein) and CR9503 (antibody recognizing both pre- and post-fùsion F protein) were used in the Flow Cytometry assays. CR9503 antibody served as a positive control. In case when F protein loses pre-fusion conformation but still is on the surface of the cell, the protein is still detected with the CR9503 antibody. Loss of staining with both antibodies indicates that protein is not available on the cell surface for antibody bînding, e.g. due to aggregatîon.
Full length proteins with three of more amino acid substitutions were tested in the assay and compared to the wild type RSV F. The expression of these variants was the highest and therefore these variants were preferred candidates. Ail of the proteins contained the N67I and S215P substitutions, and one or two extra stabilizing mutations were added.
The unmodified wîld type protein had a rather stable staining with CR9503 antibody. The MFI of the CR9503 staining was elevated at higher températures however the spread of values was also very high. This indicated that no protein aggregatîon occurred after the heat-shock. Half of the pre-fusion conformation was lost after incubation of cells at approximately 55°C, after incubation of at 60°C ail pre-fusion conformation was lost as was demonstrated by decreased CR9501 binding to the wild type F samples after heat-shock at increasing températures.
Ail tested pre-fusion F protein variants were more stable than the wild type RSV F with majority of the CR9501 staining retaining also after treatment at higher températures (Fig. 5 and 6). Proteins with K.498R amino acid substitution were less stable than the others. Addition of the K.66E mutation further stabilized the proteins as also variants with K.498R amino acid substitution became as stable as others and no loss of the pre-fusion conformation was observed at 60°C. Only selected combinations ofthe stabilizing mutations were tested with K66E and I76V combined. Ail four tested proteins were stable when percentage of positive cells was analyzed, however when MFI was analyzed variant with K498R showed clear decrease in CR9501 binding after treatment with 60°C, indicating that this variant is less stable when evaluated in the température stress assay.
In conclusion, a combination of three stabilizing mutations (including N67I and S215P) was considered sufficient for high expression level and stability. The S46G or D486N mutations was selected as a third stabilizing mutation because of their position in the protein structure. K.66E and I76V were included in the as they did not hâve négative effect on the protein expression and stability but made the sequence closer to naturally occurring ones.
Thus, the pre-fusion RSV F protein with the mutations K66E, N67I, I76V, S215P and D486N (F2.2) (SEQ ID NO: 2) and the pre-fusion RSV F protein with the mutations K66E, N67I, I76V, S215P and S46G (F2.l) (SEQ ID NO: l) were selected for the construction adénoviral vectors. These proteins were shown to be stable in the pre-fusion conformation in the température stability assay up to 60°C, and to be expressed in high levels.
Example 2. Préparation of adénoviral vectors
Cloning RSV F gene into El région of Ad35 and Ad26:
The nucleic acid sequences, coding for the pre-fusion F proteins of the invention were gene optimized for human expression and synthesized, by Geneart. A Kozak sequence (5’ GCCACC 3’) was included directly in front of the ATG start codon, and two stop codons (5’ TGA TAA 3’) were added at the end of the RSV.preF coding sequence. The RSV.pre-F genes were inserted in the pAdApt35BSU plasmid and in the pAdApt26 plasmid via HindllI and Xbal sites.
Cell culture:
PER.C6 cells (Fallaux et al., 1998, Hum Gene TherT. 1909-1917) were maintained in Dulbecco’s modified Eagle’s medium (DMEM) with 10% fêtai bovine sérum (FBS), supplemented with lOmM MgCk
Adenovirus génération, infections and passaging:
Ail adenoviruses were generated in PER.C6® cells by single homologous recombination and produced as previously described (for rAd35: Havenga et al., 2006, J. Gen. Virol. 87: 2135-2I43; for rAd26: Abbink et al., Virol. 8I: 4654-4663). Briefly, PER.C6 cells were transfected with Ad vector plasmids, using Lîpofectamine according to the instructions provided by the manufacturer (Life Technologies). For rescue of e.g, Ad35 vectors carrying the RSV.pre-F transgenes expression cassette, the pAdApt35BSU.RSV.pre-F plasmid and pWE/Ad35.pIXrITR.dE3.5orf6 cosmid were used, whereas for Ad26 vectors carrying the RSV.pre-F transgene expression cassette, the pAdApt26.RSV.pre-F plasmid and pWE.Ad26.dE3.5orf6.cosmid were used. Cells were harvested one day after full CPE, freeze-thawed, centrifuged for 5 min at 3,000 rpm, and stored at -20°C. Next the viruses were plaque purified and amplified in PER.C6 cultured on a single well of a multiwell 24 tîssue culture plate. Further amplification was carried out in PER.C6 cultured using a T25 tîssue culture flask and a Tl 75 tissue culture flask. Of theTl 75 crude lysate, 3 to 5 ml was used to inocuiate 20χΤ175 triple-layer tissue culture flasks containing 70% confluent layers of PER.C6 cells. The virus was purified using a twostep CsCl purification method. Finally, the virus was stored in aliquots at -85°C.
Example 3. Induction of immunity against RSV F using recombinant adenovirus serotypes 26 and 35 expressing pre-fusion RSV F in vivo.
The immunogenicity of Ad26.RSV.preF2.1 and Ad26.RSV.preF.2.2 was evaluated in mice, comparing cellular and humoral immune responses to responses induced by identical doses of Ad26.RSV.FA2 (i.e. expressing the wild type RSV F protein). Balb/c mice (n=4 per group) were immunized with the indicated dose of 108 to 1OI0 viral particles (vp) Ad26.RSV.FA2 or Ad26.RSV.preF2.l or Ad26.RSV.preF2.2, or with formulation buffer. At 8 weeks after prime, the number of RSV F A2 spécifie IFNy spot forming units (SFU) per 106 splénocytes was determined using ELISpot. It was shown that Ad26.RSV.preF2.l and Ad26.RSV.preF.2.2 induced increased humoral immune responses in mice when compared to Ad26.RSV.FA2, with broad neutralizing capacity and maintained cellular responses. A single intramuscular immunization with Ad26.RSV.preF2.1 and Ad26.RSV.preF.2.2 elicited a cellular response (Fig. 7) which was characterized by induction of CD8+ T cells positive for IFNy, IL2 and/or TNFa (data not shown).
The quantity and quality of the cellular responses were comparable between Ad26.RSV.preF2.l, Ad26.RSV.preF.2.2 and Ad26.RSV.FA2. In contrast, Ad26.RSV.preF2.l and Ad26.RSV.preF.2.2 induced significantly higher RSV neutralizing antibody titers than Ad26.RSV.FA2. Closer analysis of the antibody responses demonstrated that Ad26.RSV.preF2.l and Ad26.RSV.preF.2.2 induced higher levels of antibodies against pre-fusion F, while post-fusion F titers remained comparable to Ad26.RSV.FA2, resulting in significantly increased preF/postF antibody ratios. In addition, the IgG2a/IgGl ratio of the antibody response remained unaltered, demonstrating a similar Thl skewing of the humoral response as previously demonstrated for Ad26.RSV.FA2 (Fig. 8).
For Ad26.RSV.preF2.2 it was furthermore demonstrated that the antibodies elicited were capable of neutralizing varions RSV A and B strains, laboratory strains as well as clinical isolâtes, similar as observed for Ad26.RSV.FA2 (Fig. 9).
Subsequently, the efficacy and immunogenicity of Ad26.RSV.preF2.2 and Ad35.RSV.preF2.2 vector constructs was evaluated in the cotton rat model. These animais are permissive to réplication of human RSV, with peak RSV titers in the lungs at days 4 and 5. Control groups in the experiments included groups intranasally infected with a low dose RSV A2, thereby mimicking natural exposure, as well as groups immunized with FI-RSV, using the original lot 100 that induced enhanced respiratory disease (ERD) in clinical studies in the dilution that was shown to induce ERD in cotton rats.
Single intramuscular immunization of animais with Ad26.RSV.preF2.2 in doses ranging from 105 to I08 vp/animal, or Ad35.RSV.preF2.2 in doses ranging from 106 to 109 vp/animal resulted in complété protection of the lungs from infection with the vaccine homologous RSV A2 strain, except for 3 animais immunized with 105 vp Ad26.RSV.preF2.2 (Fig. 10A and 10B). Dose dépendent protection of RSV réplication in the nose was observed for both vectors. This ranged from full protection g at 10 vp/animal, to partial protection at 105 vp for Ad26.RSV.preF2.2, whereas for Ad35.RSV.preF2,2, noses of animais immunized with 109 vp were fully protected from RSV A2, and 106 vp resulted in partial protection (Fig. 10C and 10D) Noses of animais immunized with Ad26.RSV.preF2.2 and Ad35.RSV.preF2.2 were better protected from RSV A2 infection than when immunized with their respective wild type F counterparts Ad26.RSV.FA2 and Ad35.RSV.FA2, when analyzed across dose (p-0.0003, and p=0,000l). Protection from RSV infection was accompanied by dosedependent induction of virus neutralization titers against RSV A Long, already elicited by the lowest doses of Ad26.RSV.preF2.2 or Ad35.RSV.preF2.2 applied (Figure Ι0Ε and 10F). Across dose statistical comparisons of VNA A Long titers revealed that Ad26.RSV.preF2.2 is more immunogenic than Ad26.RSV.FA2 (p=0.0414), whereas elicitation of VNA titers was not significantly different between Ad35.RSV.preF2.2 and Ad35.RSV.FA2.
It was further demonstrated that Ad26.RSV.preF and Ad35.RSV.preF do not induce histopathological signs of Enhanced Respiratory Disease (ERD) after RSV A2 challenge, at any of the concentrations tested. The cotton rat is the most used and best studied model to monitor ERD. In this animal model, vaccination with Fl-RSV consistently induces ERD after RSV challenge, which is visible by histopathological analysis of sections of the infected lungs for parameters as alveolitits, consisting primarily of neutrophil infiltrâtes, and peribronchiolitis, consisting primarily of lymphocyte infiltrâtes. In cotton rats, FI-RSV-induced scores for these parameters can be observed from day l after RSV infection, and peak at 4 to 5 days after RSV challenge.
ERD was analyzed 5 days after challenge with RSV A2 by scoring 4 parameters of pulmonary inflammatory changes (peribronchiolitis, perivasculitis, interstitial pneumonia, alveolitis). Immunization with FI-RSV resulted in enhanced scores for most histopathological markers, which was especially apparent for alveolitis (Fig. 11), the marker that was previously shown to be the most discriminating marker for ERD. No increases in alveolitis or any other ERD histopathological marker was observed in animais immunized by either Ad26.RSV.preF2.2 or Ad35.RSV.preF2.2 in a prime-only regimen after RSV challenge, even at low vaccine doses that may induce low affinity and/or low levels of antibodies (Fig. U). This is confirming our previous results with Ad26.RSV.FA2 and Ad35.RSV.FA2 vectors.
According to the invention, it has thus been shown that Ad26.RSV.preF and Ad35.RSV.preF are potent adénoviral vectors expressing RSV F A2 which is stabilized in the pre-fusion conformation. These vectors induce strong humoral and cellular immune responses. The immune response elicited is protective against RSV A2 challenge and provides a wide range of virus neutralization in vitro against clinical and laboratory isolâtes of RSV. No ERD induction was observed in cotton rats after RSV exposure of vaccinated animais and therefore confirms the data generated with Ad26 and Ad35 encoding for the wild type RSV F A2 antigen. Neither mice nor cotton rats showed overt signs of reactogenicity after injection of either Ad26.RSV.preF or Ad35.RSV.preF.
Table 1. Amino acid sequences of the RSV pre-fusion F proteins encoded by the nucleic acid molécules of the invention (mutations are underlined)
SEQ ID NO: 1 : RSV preF2.1 amino acid sequence:
MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYTSVITIELSNIKEIKCNGTDA KVKLIKQELDKYKNAVTELQLLMQSTPATNNRARRELPRFMNYTLNNAKKTNVTLSKKRKRRFLGFLLGV GSAIASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTSKVLDLKNYtDKQLLPIVNKQSCSIPNIE TVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPiTNDQKKLMSNNVQIVRQQSYSIM S1IKEEVLAYWQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKV QSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGII KTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLA FIRKSDELLHNVNAVKSTTNIMimiVIlVILLSLIAVGLLLYCKARSTPVTLSKDClLSGINNIAFSN
SEQ ID NO: 2: RSV preF2.2 amino acid sequence:
MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLSALRTGWYTSVITIELSN1KEIKCNGTDAK VKLIKQELDKYKNAVTELQLLMQSTPATNNRARRELPRFMNYTLNNAKKTNVTLSKKRKRRFLGFLLGVG SAIASGVAVSKVLHLEGEVNKIK5ALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDKQ.LLPIVNKCISCSIPNIET VIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMS IIKEEVLAYWQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQ SNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSV1TSLGAIVSCYGKTKCTASNKNRGIIKT FSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPiINFYDPLVFPSNEFDASISQVNEKINQSLAFI RKSDELLHNVNAVKSTTNIMITTIIIVIIVILLSLIAVGLLLYCKARSTPVTLSKDQLSGINNIAFSN
Table 2. Nucléotide sequence of preferred nucleic acid molcules of the invention
SEQ ID NO: 3: codon optimized nucleic acid encoding the RSV F pre-F2.1 pre-fusion protein
PreF2.1
ATGGAGCTGCTGATCCTGAAGGCCAACGCCATCACCACCATCCTGACCGCCG TGACCTTCTGCTTCGCCAGCGGCCAGAACATCACCGAGGAGTTCTACCAGAG CACCTGCAGCGCCGTGAGCAAGGGCTACCTGGGCGCCCTGAGAACCGGCTG GTACACCAGCGTGATCACCATCGAGCTGAGCAACATCAAGGAGATCAAGTG CAACGGCACCGACGCCAAGGTGAAGCTGATCAAGCAGGAGCTGGACAAGTA CAAGAACGCCGTGACCGAGCTGCAGCTGCTGATGCAGAGCACCCCCGCCAC CAACAACAGAGCCAGAAGAGAGCTGCCCAGATTCATGAACTACACCCTGAAC AACGCCAAGAAGACCAACGTGACCCTGAGCAAGAAGAGAAAGAGAAGATTC CTGGGCTTCCTGCTGGGCGTGGGCAGCGCCATCGCCAGCGGCGTGGCCGTG AGCAAGGTGCTGCACCTGGAGGGCGAGGTGAACAAGATCAAGAGCGCCCTG CTGAGCACCAACAAGGCCGTGGTGAGCCTGAGCAACGGCGTGAGCGTGCTG ACCAGCAAGGTGCTGGACCTGAAGAACTACATCGACAAGCAGCTGCTGCCC ATCGTGAACAAGCAGAGCTGCAGCATCCCCAACATCGAGACCGTGATCGAG TTCCAGCAGAAGAACAACAGACTGCTGGAGATCACCAGAGAGTTCAGCGTG AACGCCGGCGTGACCACCCCCGTGAGCACCTACATGCTGACCAACAGCGAG CTGCTGAGCCTGATCAACGACATGCCCATCACCAACGACCAGAAGAAGCTGA TGAGCAACAACGTGCAGATCGTGAGACAGCAGAGCTACAGCATCATGAGCA TCATCAAGGAGGAGGTGCTGGCCTACGTGGTGCAGCTGCCCCTGTACGGCG TGATCGACACCCCCTGCTGGAAGCTGCACACCAGCCCCCTGTGCACCACCAA CACCAAGGAGGGCAGCAACATCTGCCTGACCAGAACCGACAGAGGCTGGTA CTGCGACAACGCCGGCAGCGTGAGCTTCTTCCCCCAGGCCGAGACCTGCAA
GGTGCAGAGCAACAGAGTGTTCTGCGACACCATGAACAGCCTGACCCTGCC CAGCGAGGTGAACCTGTGCAACGTGGACATCTTCAACCCCAAGTACGACTGC AAGATCATGACCAGCAAGACCGACGTGAGCAGCAGCGTGATCACCAGCCTG GGCGCCATCGTGAGCTGCTACGGCAAGACCAAGTGCACCGCCAGCAACAAG AACAGAGGCATCATCAAGACCTTCAGCAACGGCTGCGACTACGTGAGCAAC AAGGGCGTGGACACCGTGAGCGTGGGCAACACCCTGTACTACGTGAACAAG CAGGAGGGCAAGAGCCTGTACGTGAAGGGCGAGCCCATCATCAACTTCTAC GACCCCCTGGTGTTCCCCAGCGACGAGTTCGACGCCAGCATCAGCCAGGTG AACGAGAAGATCAACCAGAGCCTGGCCTTCATCAGAAAGAGCGACGAGCTG CTGCACAACGTGAACGCCGTGAAGAGCACCACCAACATCATGATCACCACCA TCATCATCGTGATCATCGTGATCCTGCTGAGCCTGATCGCCGTGGGCCTGCT GCTGTACTGCAAGGCCAGAAGCACCCCCGTGACCCTGAGCAAGGACCAGCT GAGCGGCATCAACAACATCGCCTTCAGCAACTGA
SEQ ID NO: 4: codon optimized nucleic acid encoding the RSV F pre-F2.2 pre-fusion protein
PreF2.2
ATGGAGCTGCTGATCCTGAAGGCCAACGCCATCACCACCATCCTGACCGCCG TGACCTTCTGCTTCGCCAGCGGCCAGAACATCACCGAGGAGTTCTACCAGAG CACCTGCAGCGCCGTGAGCAAGGGCTACCTGAGCGCCCTGAGAACCGGCTG GTACACCAGCGTGATCACCATCGAGCTGAGCAACATCAAGGAGATCAAGTG CAACGGCACCGACGCCAAGGTGAAGCTGATCAAGCAGGAGCTGGACAAGTA CAAGAACGCCGTGACCGAGCTGCAGCTGCTGATGCAGAGCACCCCCGCCAC CAACAACAGAGCCAGAAGAGAGCTGCCCAGATTCATGAACTACACCCTGAAC AACGCCAAGAAGACCAACGTGACCCTGAGCAAGAAGAGAAAGAGAAGATTC CTGGGCTTCCTGCTGGGCGTGGGCAGCGCCATCGCCAGCGGCGTGGCCGTG AGCAAGGTGCTGCACCTGGAGGGCGAGGTGAACAAGATCAAGAGCGCCCTG CTGAGCACCAACAAGGCCGTGGTGAGCCTGAGCAACGGCGTGAGCGTGCTG ACCAGCAAGGTGCTGGACCTGAAGAACTACATCGACAAGCAGCTGCTGCCC ATCGTGAACAAGCAGAGCTGCAGCATCCCCAACATCGAGACCGTGATCGAG TTCCAGCAGAAGAACAACAGACTGCTGGAGATCACCAGAGAGTTCAGCGTG AACGCCGGCGTGACCACCCCCGTGAGCACCTACATGCTGACCAACAGCGAG CTGCTGAGCCTGATCAACGACATGCCCATCACCAACGACCAGAAGAAGCTGA TGAGCAACAACGTGCAGATCGTGAGACAGCAGAGCTACAGCATCATGAGCA TCATCAAGGAGGAGGTGCTGGCCTACGTGGTGCAGCTGCCCCTGTACGGCG TGATCGACACCCCCTGCTGGAAGCTGCACACCAGCCCCCTGTGCACCACCAA CACCAAGGAGGGCAGCAACATCTGCCTGACCAGAACCGACAGAGGCTGGTA CTGCGACAACGCCGGCAGCGTGAGCTTCTTCCCCCAGGCCGAGACCTGCAA GGTGCAGAGCAACAGAGTGTTCTGCGACACCATGAACAGCCTGACCCTGCC CAGCGAGGTGAACCTGTGCAACGTGGACATCTTCAACCCCAAGTACGACTGC AAGATCATGACCAGCAAGACCGACGTGAGCAGCAGCGTGATCACCAGCCTG GGCGCCATCGTGAGCTGCTACGGCAAGACCAAGTGCACCGCCAGCAACAAG AACAGAGGCATCATCAAGACCTTCAGCAACGGCTGCGACTACGTGAGCAAC AAGGGCGTGGACACCGTGAGCGTGGGCAACACCCTGTACTACGTGAACAAG CAGGAGGGCAAGAGCCTGTACGTGAAGGGCGAGCCCATCATCAACTTCTAC GACCCCCTGGTGTTCCCCAGCAACGAGTTCGACGCCAGCATCAGCCAGGTG AACGAGAAGATCAACCAGAGCCTGGCCTTCATCAGAAAGAGCGACGAGCTG CTGCACAACGTGAACGCCGTGAAGAGCACCACCAACATCATGATCACCACCA TCATCATCGTGATCATCGTGATCCTGCTGAGCCTGATCGCCGTGGGCCTGCT GCTGTACTGCAAGGCCAGAAGCACCCCCGTGACCCTGAGCAAGGACCAGCT GAGCGGCATCAACAACATCGCCTTCAGCAACTGA
Claims (17)
- Claims1. Nucleic acid molécule encoding an RSV F protein that is stabîlized in the précision conformation (pre-fusion RSV F protein), wherein the RSV F protein comprises the amino acid sequence of SEQ ID NO: l or 2.
- 2. Nucleic acid molécule according to claim l, wherein the nucleic acid encoding the pre-fiision RSV F protein is codon optimized for expression in human cells.
- 3. Nucleic acid molécule according to claim l or 2, wherein the nucleic acid encoding the pre-fiision RSV F protein comprises the nucleic acid sequence of SEQ ID NO: 3 or 4.
- 4. Vector comprising the nucleic acid molécule according to claim l, 2 or 3.
- 5. Vector according to claim 4, wherein the vector is a human recombinant adenovirus.
- 6. Vector according to claim 5, wherein the recombinant human adenovirus has a délétion in the El région, a délétion in the E3 région, or a délétion in both the El and the E3 région of the adénoviral genome.
- 7. Vector according to claim 5 or 6, wherein the adenovirus is of serotype 26 or35.
- 8. Vector according to claim 5, 6 or 7, wherein the recombinant adenovirus has a genome comprising at its 5’ terminal ends the sequence CTATCTAT.
- 9. Pharmaceutical composition comprising a nucleic acid molécule according to claim l, 2 or 3.
- 10. Pharmaceutical composition comprising a vector accroding to any one of the claims 5-8.
- 11. Use of a composition according to claim 9 or 10 in the manufacture of a médicament for vaccinating a subject against RSV.
- 12. A use according to claim 11, wherein said RSV F protein is for administration to the subject.
- 13. Use of a composition comprising a nucleic acid encoding a pre-fusion RSV F protein or fragment thereof according to claim l, 2 or 3 in the manufacture of a médicament for reducing infection and/or réplication of RSV in a subject.
- 14. Use of a composition comprising a vector according to any one of the daims5-8 in the manufacture of a médicament for reducing infection and/or réplication of RSV in a subject.
- 15. An isolated host cell comprising a nucleic acid encoding a pre-fusion RSV F5 protein or fragment thereof according to claim l, 2 or 3,
- 16. A method for making a vaccine against respiratory syncytial virus (RSV), comprising providing a recombinant human adenovirus that comprises nucleic acid encoding a pre-fusion RSV F protein or fragment thereof, propagating said recombinant adenovirus in a culture of host cells, isolating and purifying the recombinant adenovirus, and formulating the recombinant adenovirus in a pharmaceuticaily acceptable composition, wherein the pre-fusion RSV F protein comprises the amino acid sequence of SEQ ID NO: l or 2.
- 17. An isolated recombinant nucleic acid that forms the genome of a recombinant human adenovirus that comprises nucleic acid encoding a pre-fusion RSV F15 protein or fragment thereof, wherein the pre-fusion RSV F protein comprises the amino acid sequence of SEQ ID NO: 1 or 2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16163807.7 | 2016-04-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA18878A true OA18878A (en) | 2019-09-13 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11801297B2 (en) | Vaccine against RSV | |
| US20220133878A1 (en) | Method for the safe induction of immunity against rsv | |
| CA2867950C (en) | Vaccine against rsv | |
| US9125870B2 (en) | Vaccine against RSV | |
| OA18878A (en) | Vaccine against RSV | |
| NZ785676A (en) | Vaccine against rsv | |
| EA043031B1 (en) | RSV VACCINE | |
| PH12014502013B1 (en) | Vaccine against rsv |